IL279173B2 - Heterocyclic compounds as monoacylglycerol lipase inhibitors, processes for their manufacture, pharmaceutical compositions comprising them, and uses thereof - Google Patents
Heterocyclic compounds as monoacylglycerol lipase inhibitors, processes for their manufacture, pharmaceutical compositions comprising them, and uses thereofInfo
- Publication number
- IL279173B2 IL279173B2 IL279173A IL27917320A IL279173B2 IL 279173 B2 IL279173 B2 IL 279173B2 IL 279173 A IL279173 A IL 279173A IL 27917320 A IL27917320 A IL 27917320A IL 279173 B2 IL279173 B2 IL 279173B2
- Authority
- IL
- Israel
- Prior art keywords
- carbonyl
- oxazin
- compound
- formula
- alkyl
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Description
279173/- 1 - HETEROCYCLIC COMPOUNDS AS MONOACYLGLYCEROL LIPASE INHIBITORS, PROCESSES FOR THEIR MANUFACTURE, PHARMACEUTICAL COMPOSITIONS COMPRISING THEM, AND USES THEREOF Field of the Invention The present invention relates to organic compounds useful for therapy or prophylaxis in a mammal, and in particular to monoacylglycerol lipase (MAGL) inhibitors for the treatment or prophylaxis of neuroinflammation, neurodegenerative diseases, pain, cancer, mental disorders, multiple sclerosis, Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis, traumatic brain injury, neurotoxicity, stroke, epilepsy, anxiety, migraine and/or depression in a mammal.
Background of the Invention Endocannabinoids (ECs) are signaling lipids that exert their biological actions by interacting with cannabinoid receptors (CBRs), CB1 and CB2. They modulate multiple physiological processes including neuroinflammation, neurodegeneration and tissue regeneration (Iannotti, F.A., et al., Progress in lipid research 2016 , 62, 107-28.). In the brain, the main endocannabinoid, 2-arachidonoylglycerol (2-AG), is produced by diacyglycerol lipases (DAGL) and hydrolyzed by the monoacylglycerol lipase, MAGL. MAGL hydrolyses 85% of 2-AG; the remaining 15% being hydrolysed by ABHD6 and ABDH12 (Nomura, D.K., et al., Science 2011 , 334, 809.). MAGL is expressed throughout the brain and in most brain cell types, including neurons, astrocytes, oligodendrocytes and microglia cells (Chanda, P.K., et al., Molecular pharmacology 2010 , 78, 996; Viader, A., et al., Cell reports 2015 , 12, 798.). 2-AG hydrolysis results in the formation of arachidonic acid (AA), the precursor of prostaglandins (PGs) and leukotrienes (LTs). Oxidative metabolism of AA is increased in inflamed tissues. There are two principal enzyme pathways of arachidonic acid oxygenation involved in inflammatory processes, the cyclo-oxygenase which produces PGs and the 5-lipoxygenase which produces LTs. Of the various cyclooxygenase products formed during inflammation, PGE2 is one of the most important. These products have been detected at sites of inflammation, e.g. in the cerebrospinal
Claims (53)
1. A compound of formula (I) mnA(I) or a pharmaceutically acceptable salt thereof, wherein: (i) X is C-R; m is 0 or 1; n is selected from 0, 1 and 2; and L is selected from –(CH)p–, –O–, –OCH–, –CHOCH–, –CFCH–, –CH=CH–, –(CRR)q-CHO–, and –CHCF–; or (ii) X is N; m is 1; n is 1 or 2; and L is –(CH)p– or –CFCH–; p is selected from 1, 2 and 3; q is 0 or 1; A is selected from: (i) C-C-aryl substituted with R, R and R; (ii) 5- to 14-membered heteroaryl substituted with R, R and R; and (iii) 3- to 14-membered heterocycloalkyl substituted with R, R and R; R is hydrogen or C1-6-alkyl; R is selected from hydrogen, C1-6-alkyl and hydroxy-C1-6-alkyl; R is selected from hydrogen, halogen, hydroxy, C1-6-alkoxy, C1-6-alkyl and halo-C1--alkyl; each of R, R, R, R, R, R, R, R and R is independently selected from hydrogen, halogen, cyano, hydroxy, C1-6-alkyl, halo-C1-6-alkyl, hydroxy-C1-6-alkyl, C1-6-alkanoyl, halo-C1-5-alkyl-CH(OH)–, C1-6-alkoxy, halo-C1-6-alkoxy, SF, CHSO, C3-10-cycloalkyl, C3-10-cycloalkyl substituted with R, 3- to 14-membered heterocycloalkyl, 3- to 14-membered heterocycloalkyl substituted with R and R, 5- to 14-membered heteroaryl, C-C-aryl, C-C-aryloxy, halo-C-C-aryl, and halo-C-C-aryloxy; each of R, R, and R is independently selected from C1-6-alkyl, C1-6-alkoxy, halo-C1-6-alkyl, halo-C1-6-alkoxy, halogen, and hydroxy; and R and R, taken together with the carbon atom to which they are attached, form a C3-10-cycloalkyl; 30 279173/- 263 - provided that said compound of formula (I) is not (4aS,8aS)-hexahydro-6-[[4-(phenylmethyl)-1-piperidinyl]carbonyl]-2H-pyridol[4,3-b]-1,4-oxazin-3(4H)-one.
2. The compound of formula (I) according to claim 1, or a pharmaceutically acceptable salt thereof, wherein the compound of formula (I) is a compound of formula (Ia): mnA (Ia) wherein A, L, X, m, n, R and R are as defined in claim 1.
3. The compound of formula (I) according to claim 1, or a pharmaceutically acceptable salt thereof, wherein the compound of formula (I) is a compound of formula (Ib): mnA (Ib) wherein A, L, X, m, n, R and R are as defined in claim 1.
4. The compound of formula I according to any one of claims 1-3, or a pharmaceutically acceptable salt thereof, wherein: (i) X is C-R; m is 0 or 1; n is selected from 0, 1 and 2; and L is selected from –(CH)p–, –O–, –OCH–, –CFCH–, –CH=CH–, –(CRR)q-CHO–, and – CHOCH–; or (ii) X is N; m and n are both 1; and L is –(CH)p–.
5. The compound of formula I according to any one of claims 1-4, or a pharmaceutically acceptable salt thereof, wherein: X is C-R; m and n are both 0; or m and n are both 1; and L is selected from –(CH)p–, –O–, –OCH– and –CHO–.
6. The compound of formula I according to any one of claims 1-5, or a pharmaceutically acceptable salt thereof, wherein p is 1 or 2. 25 279173/- 264 -
7. The compound of formula I according to any one of claims 1-5, or a pharmaceutically acceptable salt thereof, wherein p is 2.
8. The compound of formula I according to any one of claims 1-7, or a pharmaceutically acceptable salt thereof, wherein q is 0 or 1.
9. The compound of formula I according to any one of claims 1-7, or a pharmaceutically acceptable salt thereof, wherein q is 0.
10. The compound of formula I according to any one of claims 1-9, or a pharmaceutically acceptable salt thereof, wherein A is selected from: (i) C-C-aryl substituted with R, R and R; and (ii) 5- to 14-membered heteroaryl substituted with R, R and R.
11. The compound of formula I according to any one of claims 1-9, or a pharmaceutically acceptable salt thereof, wherein A is selected from: (i) phenyl substituted with R, R and R; (ii) oxazolyl substituted with R, R and R; and (iii) pyridyl substituted with R, R and R.
12. The compound of formula I according to any one of claims 1-11, or a pharmaceutically acceptable salt thereof, wherein R is hydrogen.
13. The compound of formula I according to any one of claims 1-12, or a pharmaceutically acceptable salt thereof, wherein R is hydrogen or C1-6-alkyl.
14. The compound of formula I according to any one of claims 1-12, or a pharmaceutically acceptable salt thereof, wherein R is hydrogen or methyl.
15. The compound of formula I according to any one of claims 1-14, or a pharmaceutically acceptable salt thereof, wherein R is selected from hydrogen, halogen, C1-6-alkyl and halo-C1-6-alkyl.
16. The compound of formula I according to any one of claims 1-14, or a pharmaceutically acceptable salt thereof, wherein R is selected from hydrogen, halogen and C1-6-alkyl. 279173/- 265 -
17. The compound of formula I according to any one of claims 1-14, or a pharmaceutically acceptable salt thereof, wherein R is selected from hydrogen, fluoro and methyl.
18. The compound of formula I according to any one of claims 1-17, or a pharmaceutically acceptable salt thereof, wherein R is selected from hydrogen, halogen, hydroxy, cyano, C1-6-alkyl, C1-6-alkanoyl, SF, C1-6-alkoxy, halo-C1-6-alkoxy, halo-C1-6-alkyl, C3-10-cycloalkyl, 3- to 14-membered heterocyclyl, 3- to 14-membered heterocycloalkyl substituted with R and R, 5- to 14-membered heteroaryl, C-C-aryloxy, and halo-C-C-aryl.
19. The compound of formula I according to any one of claims 1-17, or a pharmaceutically acceptable salt thereof, wherein R is selected from halogen, SF, C1-6-alkyl, C1-6-alkoxy, halo-C1-6-alkoxy, halo-C1-6-alkyl, C3-10-cycloalkyl, and 3- to 14-membered heterocycloalkyl.
20. The compound of formula I according to any one of claims 1-17, or a pharmaceutically acceptable salt thereof, wherein R is selected from chloro, SF, methyl, methoxy, OCF, CF, cyclopropyl, and 2-azaspiro[3.3]heptan-2-yl.
21. The compound of formula I according to any one of claims 1-20, or a pharmaceutically acceptable salt thereof, wherein R is selected from hydrogen, cyano, halogen, C1-6-alkyl, halo-C1-6-alkyl, C1-6-alkoxy, 3- to 14-membered heterocycloalkyl, C3-10-cycloalkyl, 5- to 14-membered heteroaryl. and halo-C-C- aryl.
22. The compound of formula I according to any one of claims 1-20, or a pharmaceutically acceptable salt thereof, wherein R is selected from hydrogen, cyano, halogen, C1-6-alkyl, halo-C1-6-alkyl, 3- to 14-membered heterocycloalkyl, C3--cycloalkyl and halo-C-C-aryl.
23. The compound of formula I according to any one of claims 1-20, or a pharmaceutically acceptable salt thereof, wherein R is selected from hydrogen, cyano, fluoro, chloro, methyl, CF, pyrrolidinyl, cyclopentyl, cyclopropyl and chlorophenyl. 279173/- 266 -
24. The compound of formula I according to any one of claims 1-23, or a pharmaceutically acceptable salt thereof, wherein R is hydrogen or halogen.
25. The compound of formula I according to any one of claims 1-23, or a pharmaceutically acceptable salt thereof, wherein R is hydrogen.
26. The compound of formula I according to any one of claims 1-25, or a pharmaceutically acceptable salt thereof, wherein R is selected from hydrogen, C1-6-alkyl, C-C-aryl, halo-C-C-aryl, halo-C-C-aryloxy, and halo-C1-6-alkyl.
27. The compound of formula I according to any one of claims 1-25, or a pharmaceutically acceptable salt thereof, wherein R is C1-6-alkyl or halo-C1-6-alkyl.
28. The compound of formula I according to any one of claims 1-25, or a pharmaceutically acceptable salt thereof, wherein R is tert-butyl or CF.
29. The compound of formula I according to any one of claims 1-28, or a pharmaceutically acceptable salt thereof, wherein R is selected from hydrogen, halogen, C1-6-alkyl, and halo-C1-6-alkyl.
30. The compound of formula I according to any one of claims 1-28, or a pharmaceutically acceptable salt thereof, wherein R is hydrogen or halo-C1-6-alkyl.
31. The compound of formula I according to any one of claims 1-28, or a pharmaceutically acceptable salt thereof, wherein R is hydrogen or CF.
32. The compound of formula I according to any one of claims 1-31, or a pharmaceutically acceptable salt thereof, wherein R is hydrogen.
33. The compound of formula I according to any one of claims 1-32, or a pharmaceutically acceptable salt thereof, wherein R is halogen.
34. The compound of formula I according to any one of claims 1-33, or a pharmaceutically acceptable salt thereof, wherein R is halogen.
35. The compound of formula I according to any one of claims 1-34, or a pharmaceutically acceptable salt thereof, wherein R is hydrogen. 279173/- 267 -
36. The compound of formula I according to any one of claims 1-35, or a pharmaceutically acceptable salt thereof, wherein R is selected from C1-6-alkyl, C1--alkoxy, and halogen.
37. The compound of formula I according to any one of claims 1-36, or a pharmaceutically acceptable salt thereof, wherein R is hydrogen or halogen.
38. The compound of formula I according to any one of claims 1-3, or a pharmaceutically acceptable salt thereof, wherein: (i) X is C-R; m is 0 or 1; n is selected from 0, 1 and 2; and L is selected from –(CH)p–, –O–, –OCH–, –(CRR)q-CHO–, –CHOCH–, –CFCH–, and –CH=CH–; or (ii) X is N; m and n are both 1; and L is –(CH)p–; p is 1 or 2; q is 0 or 1; A is selected from: (i) C-C-aryl substituted with R, R and R; (ii) 5- to 14-membered heteroaryl substituted with R, R and R; and (iii) 3- to 14-membered heterocycloalkyl substituted with R, R and R; R is hydrogen or C1-6-alkyl; R is hydrogen or C1-6-alkyl; R is selected from hydrogen, halogen, C1-6-alkyl and halo-C1-6-alkyl; R is selected from hydrogen, halogen, cyano, SF, C1-6-alkyl, C1-6-alkanoyl, C1-6-alkoxy, halo-C1-6-alkoxy, halo-C1-6-alkyl, C3-10-cycloalkyl, 3- to 14-membered heterocycloalkyl, 3- to 14-membered heterocycloalkyl substituted with R and R, 5- to 14-membered heteroaryl, halo-C-C-aryl, and C-C-aryloxy; R is selected from hydrogen, cyano, halogen, C1-6-alkyl, halo-C1-6-alkyl, C1-6- alkoxy, 3- to 14-membered heterocycloalkyl, C3-10-cycloalkyl, 5- to 14-membered heteroaryl and halo-C-C-aryl; R is hydrogen or halogen; R is selected from hydrogen, C1-6-alkyl, C-C-aryl, halo-C-C-aryl, halo-C-C-aryloxy, and halo-C1-6-alkyl; R is selected from hydrogen,halogen, C1-6-alkyl, and halo-C1-6-alkyl; R is hydrogen; R is halogen; 279173/- 268 - R is halogen; R is hydrogen; R is selected from halogen, C1-6-alkyl, and C1-6-alkoxy; R is hydrogen or halogen; and R and R, taken together with the carbon atom to which they are attached, form a C3-10-cycloalkyl.
39. The compound of formula I according to any one of claims 1-3, or a pharmaceutically acceptable salt thereof, wherein: X is C-R; m and n are both 0; or m and n are both 1; L is selected from –(CH)p–, –O–, –OCH– and –CHO–; p is 1 or 2; A is selected from: (i) C-C-aryl substituted with R, R and R; and (ii) 5- to 14-membered heteroaryl substituted with R, R and R; R is hydrogen; R is hydrogen or C1-6-alkyl; R is selected from hydrogen, halogen and C1-6-alkyl; R is selected from halogen, SF, C1-6-alkyl, C1-6-alkoxy, halo-C1-6-alkoxy, halo-C1-6- alkyl, C3-10-cycloalkyl, and 3- to 14-membered heterocycloalkyl; R is selected from hydrogen, cyano, halogen, C1-6-alkyl, halo-C1-6-alkyl, 3- to 14-membered heterocycloalkyl, C3-10-cycloalkyl and halo-C-C-aryl; R is hydrogen; R is C1-6-alkyl or halo-C1-6-alkyl; R is hydrogen or halo-C1-6-alkyl; and R is hydrogen.
40. The compound of formula I according to any one of claims 1-3, wherein: X is C-R; m and n are both 0; or m and n are both 1; L is selected from –(CH)p–, –O–, –OCH– and –CHO–; p is 1 or 2; 279173/- 269 - A is selected from: (i) phenyl substituted with R, R and R; (ii) oxazolyl substituted with R, R and R; and (iii) pyridyl substituted with R, R and R; R is hydrogen; R is hydrogen or methyl; R is selected from hydrogen, fluoro and methyl; R is selected from chloro, SF, methyl, methoxy, OCF, CF, cyclopropyl, and 2-azaspiro[3.3]heptan-2-yl; R is selected from hydrogen, cyano, fluoro, chloro, methyl, CF, pyrrolidinyl, cyclopentyl, cyclopropyl and chlorophenyl; R is hydrogen; R is selected from tert-butyl, methyl, and CF; R is hydrogen or CF; and R is hydrogen.
41. A compound of formula (I) according to any one of claims 1 to 40, or a pharmaceutically acceptable salt thereof, selected from the compounds disclosed in Table 1.
42. A compound of formula (I) according to any one of claims 1 to 40, or a pharmaceutically acceptable salt thereof, selected from: (+)-(4aR,8aS)-6-(4-((4-(tert-Butyl)oxazol-2-yl)methyl)piperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one; (+)-(4aR,8aS)-6-[4-[[4-(Trifluoromethyl)phenyl]methyl]piperidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one; (+)-(4aR,8aS)-6-(4-((2-Chloro-4-fluorophenoxy)methyl)piperidine-1- carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one; rac-(4aR,8aS)-6-(3-((2-Fluoro-4-(trifluoromethyl)benzyl)oxy)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one; (+)- or (-)-(4aR,8aS)-6-(3-((2-Chloro-4-fluorobenzyl)oxy)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one; (+)- or (-)-(4aR,8aS)-6-(3-((2-Fluoro-4-(trifluoromethyl)benzyl)oxy)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one; 279173/- 270 - (+)- or (-)-(4aR,8aS)-6-(4-(4-(Trifluoromethoxy)benzyl)piperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one; (+)- or (-)-(4aR,8aS)-6-(4-(4-Chloro-3-fluorobenzyl)piperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one; (+)- or (-)-(4aR,8aS)-6-(4-(2-Chloro-4-(trifluoromethyl)phenoxy)piperidine-1- carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one; (+)- or (-)-(4aR,8aS)-6-(4-(3-(Trifluoromethyl)phenoxy)piperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one; (+)- or (-)-(4aR,8aS)-6-[4-[[2-Chloro-4-(trifluoromethoxy)phenoxy]methyl]piperidine-1-carbonyl]-4,4a,5,7,8,8a- hexahydropyrido[4,3-b][1,4]oxazin-3-one; (+)- or (-)-(4aR,8aS)-6-(3-((2-Fluoro-4-(trifluoromethyl)phenoxy)methyl)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one; (+)- or (-)-(4aR,8aS)-6-(4-((4-Chloro-2-fluorophenoxy)methyl)piperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one; (+)- or (-)-(4aR,8aS)-6-(4-((4-Fluoro-2-(trifluoromethyl)phenoxy)methyl)piperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one; (+)- or (-)-(4aR,8aS)-6-(4-((2-Fluoro-4-(trifluoromethyl)phenoxy)methyl)piperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one; (+)- or (-)-(4aR,8aS)-6-(4-(2-(Pyrrolidin-1-yl)-4-(trifluoromethyl)benzyl)piperidine- 1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one; (+)- or (-)-(4aR,8aS)-6-(4-((2-Chloro-4-(trifluoromethyl)phenoxy)methyl)piperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one; (+)- or (-)-(4aR,8aS)-6-[4-[[2-Cyclopentyl-4-(trifluoromethyl)phenyl]methyl]piperidine-1-carbonyl]-4,4a,5,7,8,8a- hexahydropyrido[4,3-b][1,4]oxazin-3-one; (+)- or (-)-3-Chloro-4-((1-((4aR,8aS)-3-oxooctahydro-2H-pyrido[4,3-b][1,4]oxazine-6-carbonyl)piperidin-4-yl)methoxy)benzonitrile; (+)- or (-)-(4aR,8aS)-6-(3-((2-Chloro-4-(trifluoromethyl)phenoxy)methyl)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one; (+)- or (-)-(4aR,8aS)-6-(4-((2-Chloro-4-fluorophenoxy)methyl)-4-fluoropiperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one; (+)- or (-)-(4aR,8aS)-6-(4-((4',6-Dichloro-[1,1'-biphenyl]-3-yl)oxy)piperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one; 279173/- 271 - (+)- or (-)-(4aR,8aS)-6-(cis-4-((2-Chloro-4-fluorophenoxy)methyl)-3-methylpiperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one; (+)- or (-)-(4aR,8aS)-6-(3-((2-Chloro-4-(trifluoromethyl)benzyl)oxy)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one; (+)- or (-)-(4aR,8aS)-6-(3-((2-Fluoro-4-(trifluoromethoxy)benzyl)oxy)azetidine-1- carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one; (+)- or (-)-(4aR,8aS)-6-(4-((2-Chloro-4-fluorophenoxy)methyl)-4-methylpiperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one; (4aR,8aS)-6-[3-[(2,4-Dichlorophenyl)methoxy]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one; (4aR,8aS)-6-[4-[[2-Fluoro-4-(trifluoromethyl)phenyl]methyl]piperidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one; (4aR,8aS)-6-[4-[[2-Cyclopropyl-4-(trifluoromethyl)phenyl]methyl]piperidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one; (4aR,8aS)-6-[3-[[3-Chloro-4-(trifluoromethyl)phenyl]methoxy]azetidine-1- carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one; (4aR,8aS)-6-[3-[[2-Fluoro-5-(trifluoromethyl)phenyl]methoxy]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one; (4aR,8aS)-6-[3-[2-[2-Fluoro-6-(trifluoromethyl)phenyl]ethyl]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one; (4aR,8aS)-6-(3-(2-fluoro-4-(trifluoromethyl)phenethyl)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one; 6-(3-((2,4-bis(trifluoromethyl)benzyl)oxy)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one; (4aR,8aS)-6-[4-[3-chloro-4-(trifluoromethyl)phenoxy]piperidine-1-carbonyl]- 4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one; (4aR,8aS)-6-(3-methyl-4-(((5-methyl-6-(trifluoromethyl)pyridin-3-yl)oxy)methyl)piperidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one; (4aR,8aS)-6-(3-((3,4-dichlorobenzyl)oxy)azetidine-1-carbonyl)hexahydro-2H- pyrido[4,3-b][1,4]oxazin-3(4H)-one; (4aR,8aS)-6-(3-((2,5-dichlorobenzyl)oxy)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one; 279173/- 272 - rac-(4aR,8aS)-6-(2-methyl-3-((4-methyl-3-(trifluoromethyl)benzyl)oxy)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one; (4aR,8aS)-6-(3-(((4,5-bis(trifluoromethyl)pyridin-2-yl)oxy)methyl)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one; rac-(4aR,8aS)-6-(3-((2-fluoro-4-(trifluoromethyl)benzyl)oxy)-2-methylazetidine-1- carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one; (4aR,8aS)-6-(3-((2-fluoro-4-(pentafluoro-l6-sulfaneyl)benzyl)oxy)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one; (4aR,8aS)-6-(3-((4-methyl-2-(trifluoromethoxy)benzyl)oxy)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one; (4aR,8aS)-6-[4-[3-cyclopropyl-4-(trifluoromethyl)phenoxy]piperidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one; (4aR,8aS)-6-[3-[2-(2-fluoro-4-methyl-phenyl)ethyl]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one; (4aR,8aS)-6-[3-[2-[4-methoxy-2-(trifluoromethyl)phenyl]ethyl]azetidine-1- carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one; (4aR,8aS)-6-[3-[3-(2-azaspiro[3.3]heptan-2-yl)-4-(trifluoromethyl)phenoxy]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one; (4aR,8aS)-6-[3-[2-[4-methyl-2-(trifluoromethyl)phenyl]ethyl]azetidine-1-carbonyl]- 4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one; (4aR,8aS)-6-(3-((4-methyl-3-(trifluoromethyl)benzyl)oxy)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one; (4aR,8aS)-6-(3-((2-methyl-3-(trifluoromethyl)benzyl)oxy)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one; rac-(4aR,8aS)-6-[2-methyl-3-[[2-methyl-4-(trifluoromethoxy)phenyl]methoxy]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one; rac-(4aR,8aS)-6-[2-methyl-3-[[2-methyl-3-(trifluoromethyl)phenyl]methoxy]azetidine-1-carbonyl]-4,4a,5,7,8,8a- hexahydropyrido[4,3-b][1,4]oxazin-3-one; (4aR,8aS)-6-[3-(4-chloro-3-cyclopropylphenoxy)azetidine-1-carbonyl]-4,4#a!,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one; 279173/- 273 - (4aR,8aS)-6-[4-[2-chloro-3-(trifluoromethyl)phenoxy]piperidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one; (4aR,8aS)-6-[3-(2-chloro-3-cyclopropyl-phenoxy)azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one; (4aR,8aS)-6-[3-[3-(2-azaspiro[3.3]heptan-2-yl)-2-chloro-phenoxy]azetidine-1- carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one; (4aR,8aS)-6-[3-[2-chloro-3-(5-oxa-2-azaspiro[3.5]nonan-2-yl)phenoxy]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one; (4aR,8aS)-6-[3-[(E)-2-(2-fluoro-4-methyl-phenyl)vinyl]azetidine-1-carbonyl]-4,4a,5,7,8,8a-hexahydropyrido[4,3-b][1,4]oxazin-3-one; (4aR,8aS)-6-(3-((E)-2-fluoro-6-(trifluoromethyl)styryl)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one; and (4aR,8aS)-6-(3-((4-methyl-3-(trifluoromethyl)benzyl)oxy)azetidine-1-carbonyl)hexahydro-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one.
43. The compound of formula (I) according to claim 1, which is: or a pharmaceutically acceptable salt thereof.
44. The compound of formula (I) according to claim 1, which is: or a pharmaceutically acceptable salt thereof. 279173/- 274 -
45. The compound of formula (I) according to claim 1, which is: or a pharmaceutically acceptable salt thereof.
46. The compound of formula (I) according to claim 1, which is: or a pharmaceutically acceptable salt thereof.
47. The compound of formula (I) according to claim 1, which is: or a pharmaceutically acceptable salt thereof.
48. The compound of formula (I) according to claim 1, which is: or a pharmaceutically acceptable salt thereof.
49. A process of manufacturing the compounds of formula (I) according to any one of claims 1 to 48, or a compound which is (4aS,8aS)-hexahydro-6-[[4-(phenylmethyl)-1-piperidinyl]carbonyl]-2H-pyridol[4,3-b]-1,4-oxazin-3(4H)-one, or pharmaceutically acceptable salts thereof, the process comprising: 20 279173/- 275 - reacting a first amine of formula 1 , wherein R is as described in any one of claims to 48, 1 with a second amine of formula 2 , wherein A, L, m, n, X and R are as described in any one of claims 1 to 48 mnA in the presence of a base and a urea forming reagent, wherein said urea forming agent is selected from bis(trichloromethyl) carbonate, phosgene, trichloromethyl chloroformate, (4-nitrophenyl)carbonate and 1,1’-carbonyldiimidazole.
50. A compound of formula (I) according to any one of claims 1 to 48, or a compound which is (4aS,8aS)-hexahydro-6-[[4-(phenylmethyl)-1-piperidinyl]carbonyl]-2H-pyridol[4,3-b]-1,4-oxazin-3(4H)-one, or a pharmaceutically acceptable salt thereof, for use as therapeutically active substance.
51. A pharmaceutical composition comprising a compound of formula (I) according to any one of claims 1 to 48, or a compound which is (4aS,8aS)-hexahydro-6-[[4-(phenylmethyl)-1-piperidinyl]carbonyl]-2H-pyridol[4,3-b]-1,4-oxazin-3(4H)-one, or a pharmaceutically acceptable salt thereof, and a therapeutically inert carrier.
52. A compound of formula (I) according to any one of claims 1 to 48, or a compound which is (4aS,8aS)-hexahydro-6-[[4-(phenylmethyl)-1-piperidinyl]carbonyl]-2H- pyridol[4,3-b]-1,4-oxazin-3(4H)-one, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition according to claim 51, for use in the treatment or prophylaxis of neuroinflammation, neurodegenerative diseases, pain, cancer and/or mental disorders in a mammal.
53. A compound of formula (I) according to any one of claims 1 to 48, or a compound which is (4aS,8aS)-hexahydro-6-[[4-(phenylmethyl)-1-piperidinyl]carbonyl]-2H- 279173/- 276 - pyridol[4,3-b]-1,4-oxazin-3(4H)-one, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition according to claim 51, for use in the treatment or prophylaxis of multiple sclerosis, Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis, traumatic brain injury, neurotoxicity, stroke, epilepsy, anxiety, migraine, depression, hepatocellular carcinoma, colon carcinogenesis, ovarian cancer, neuropathic pain, chemotherapy induced neuropathy, acute pain, chronic pain and/or spasticity associated with pain in a mammal.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18188681 | 2018-08-13 | ||
| PCT/EP2019/071520 WO2020035424A1 (en) | 2018-08-13 | 2019-08-12 | New heterocyclic compounds as monoacylglycerol lipase inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| IL279173A IL279173A (en) | 2021-01-31 |
| IL279173B1 IL279173B1 (en) | 2025-01-01 |
| IL279173B2 true IL279173B2 (en) | 2025-05-01 |
Family
ID=63244467
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL279173A IL279173B2 (en) | 2018-08-13 | 2019-08-12 | Heterocyclic compounds as monoacylglycerol lipase inhibitors, processes for their manufacture, pharmaceutical compositions comprising them, and uses thereof |
Country Status (33)
| Country | Link |
|---|---|
| US (4) | US20200308190A1 (en) |
| EP (2) | EP3837263B1 (en) |
| JP (2) | JP7637049B2 (en) |
| KR (1) | KR102879259B1 (en) |
| CN (1) | CN112867720A (en) |
| AR (1) | AR116666A1 (en) |
| AU (1) | AU2019322538B2 (en) |
| BR (1) | BR112021002298A2 (en) |
| CA (1) | CA3104928A1 (en) |
| CL (1) | CL2021000362A1 (en) |
| CO (1) | CO2021002382A2 (en) |
| CR (1) | CR20210077A (en) |
| DK (1) | DK3837263T3 (en) |
| ES (1) | ES2986417T3 (en) |
| FI (1) | FI3837263T3 (en) |
| HR (1) | HRP20241201T1 (en) |
| HU (1) | HUE067912T2 (en) |
| IL (1) | IL279173B2 (en) |
| LT (1) | LT3837263T (en) |
| MA (1) | MA53219B1 (en) |
| MX (1) | MX2021001433A (en) |
| MY (1) | MY210507A (en) |
| PE (1) | PE20211089A1 (en) |
| PH (1) | PH12021500013A1 (en) |
| PL (1) | PL3837263T3 (en) |
| PT (1) | PT3837263T (en) |
| RS (1) | RS65912B1 (en) |
| RU (1) | RU2769507C1 (en) |
| SG (1) | SG11202013064WA (en) |
| SI (1) | SI3837263T1 (en) |
| TW (1) | TWI812770B (en) |
| UA (1) | UA127629C2 (en) |
| WO (1) | WO2020035424A1 (en) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR114136A1 (en) | 2017-10-10 | 2020-07-29 | Hoffmann La Roche | HETEROCYCLIC COMPOUNDS |
| EP3717477B1 (en) | 2017-11-28 | 2022-07-20 | F. Hoffmann-La Roche AG | New heterocyclic compounds |
| EP3737680A1 (en) | 2018-01-08 | 2020-11-18 | F. Hoffmann-La Roche AG | Octahydropyrido[1,2-alpha]pyrazines as magl inhibitors |
| AU2019227607C1 (en) | 2018-02-27 | 2023-07-20 | Incyte Corporation | Imidazopyrimidines and triazolopyrimidines as A2A / A2B inhibitors |
| EP3810610A1 (en) | 2018-05-18 | 2021-04-28 | Incyte Corporation | Fused pyrimidine derivatives as a2a / a2b inhibitors |
| CN117304191A (en) | 2018-07-05 | 2023-12-29 | 因赛特公司 | Fused pyrazine derivatives as A2A/A2B inhibitors |
| MY210507A (en) | 2018-08-13 | 2025-09-28 | Hoffmann La Roche | New heterocyclic compounds as monoacylglycerol lipase inhibitors |
| WO2020104494A1 (en) | 2018-11-22 | 2020-05-28 | F. Hoffmann-La Roche Ag | New heterocyclic compounds |
| TWI829857B (en) | 2019-01-29 | 2024-01-21 | 美商英塞特公司 | Pyrazolopyridines and triazolopyridines as a2a / a2b inhibitors |
| CN114072405A (en) | 2019-07-03 | 2022-02-18 | 豪夫迈·罗氏有限公司 | Heterocyclic monoacylglycerol lipase (MAGL) inhibitors |
| KR20220034104A (en) | 2019-07-09 | 2022-03-17 | 에프. 호프만-라 로슈 아게 | Novel heterocyclic compounds |
| KR20220058553A (en) * | 2019-09-05 | 2022-05-09 | 루난 파마슈티컬 그룹 코퍼레이션 | MAGL inhibitors and methods for their preparation, uses |
| US20210094971A1 (en) * | 2019-09-09 | 2021-04-01 | Hoffmann-La Roche Inc. | Heterocyclic compounds |
| PH12022550339A1 (en) | 2019-09-12 | 2023-03-13 | Hoffmann La Roche | 4,4a,5,7,8,8a-hexapyrido[4,3-b][1,4]oxazin-3-one compounds as magl inhibitors |
| MX2022003023A (en) * | 2019-09-23 | 2022-04-07 | Hoffmann La Roche | HETEROCYCLIC COMPOUNDS. |
| MX2022002831A (en) * | 2019-09-24 | 2022-04-06 | Hoffmann La Roche | HETEROCYCLIC COMPOUNDS. |
| CA3152213A1 (en) * | 2019-09-24 | 2021-04-01 | F. Hoffmann-La Roche Ag | New heterocyclic monoacylglycerol lipase (magl) inhibitors |
| ES3074115T3 (en) | 2019-10-07 | 2026-07-17 | De Shaw Res Llc | Arylmethylene heterocyclic compounds as blockers of Shaker-type potassium channels Kv1.3 |
| CA3176113A1 (en) * | 2020-03-26 | 2021-09-30 | Janssen Pharmaceutica Nv | Aminocyclobutanes as monoacylglycerol lipase modulators |
| PE20231372A1 (en) | 2020-09-03 | 2023-09-07 | Hoffmann La Roche | HETEROCYCLIC COMPOUNDS |
| IL313987A (en) | 2021-12-29 | 2024-08-01 | Psy Therapeutics Inc | Inhibition of monoacylglycerol lipase (MAGL) |
| AU2023320565A1 (en) | 2022-08-05 | 2025-01-23 | Kumquat Biosciences Inc. | Heterocyclic compounds and uses thereof |
| WO2024168426A1 (en) | 2023-02-13 | 2024-08-22 | Apogee Pharmaceuticals, Inc. | Small molecules as monoacylglycerol lipase (magl) inhibitors, compositions and use thereof |
Family Cites Families (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5214038A (en) | 1991-04-15 | 1993-05-25 | Hoechst-Roussel Pharmaceuticals Inc. | 1-(pyrido[3,4-b]-1,4-oxazinyl-4-yl)-1H-indoles and intermediates for the preparation thereof |
| US7544678B2 (en) | 2002-11-05 | 2009-06-09 | The Trustees Of Columbia University In The City Of New York | Anti-arrythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) |
| US7160888B2 (en) | 2003-08-22 | 2007-01-09 | Warner Lambert Company Llc | [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia |
| US7579495B2 (en) | 2003-12-19 | 2009-08-25 | Momentive Performance Materials Inc. | Active-releasing cyclic siloxanes |
| AU2006230364B2 (en) | 2005-03-31 | 2012-09-13 | Janssen Pharmaceutica N.V. | Bicyclic pyrazole compounds as antibacterial agents |
| CA2609957A1 (en) | 2005-06-20 | 2007-01-04 | Schering Corporation | Carbon-linked substituted piperidines and derivatives thereof useful as histamine h3 antagonists |
| EP1945222B1 (en) | 2005-11-02 | 2012-12-26 | Bayer Pharma Aktiengesellschaft | Pyrrolo[2,1-f] [1,2,4]-triazin-4-ylamines as igf-1r kinase inhibitors for the treatment of cancer and other hyperproliferative diseases |
| EP1984351A1 (en) | 2006-02-17 | 2008-10-29 | Memory Pharmaceuticals Corporation | Compounds having 5-ht6 receptor affinity |
| WO2007117557A2 (en) | 2006-04-05 | 2007-10-18 | Vitae Pharmaceuticals, Inc. | Diaminopropanol renin inhibitors |
| MX394214B (en) | 2007-03-12 | 2025-03-24 | Intra Cellular Therapies Inc | SYNTHESIS OF FUSED GAMMA-CARBOLINES WITH SUBSTITUTED HETEROCYCLES. |
| FR2915197B1 (en) * | 2007-04-18 | 2009-06-12 | Sanofi Aventis Sa | TRIAZOLOPYRIDINE CARBOXAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF. |
| TW200942537A (en) | 2008-02-01 | 2009-10-16 | Irm Llc | Compounds and compositions as kinase inhibitors |
| PT2266989E (en) | 2008-03-31 | 2015-11-23 | C&C Res Lab | Heterocyclic derivatives |
| CA2741153A1 (en) | 2008-10-29 | 2010-05-06 | F. Hoffmann-La Roche Ag | Novel phenyl amide or pyridyl amide derivatives and their use as gpbar1 agonists |
| MX2012002641A (en) | 2009-09-10 | 2012-03-14 | Hoffmann La Roche | Inhibitors of jak. |
| WO2011059118A1 (en) | 2009-11-10 | 2011-05-19 | Kim Hyun Jeen | System for testing olfactory perception |
| US9051296B2 (en) * | 2009-11-16 | 2015-06-09 | Raqualia Pharma Inc. | Aryl carboxamide derivatives as TTX-S blockers |
| US8420661B2 (en) | 2010-04-13 | 2013-04-16 | Hoffmann-La Roche Inc. | Arylethynyl derivatives |
| WO2012155199A1 (en) | 2011-05-16 | 2012-11-22 | Bionomics Limited | Amine derivatives as potassium channel blockers |
| WO2013059118A1 (en) | 2011-10-19 | 2013-04-25 | The Trustees Of Columbia University In The City Of New York | Cyclopropenimine catalyst compositions and processes |
| TW201326180A (en) | 2011-11-30 | 2013-07-01 | Actelion Pharmaceuticals Ltd | 3,7-disubstituted octahydro-2H-pyrido[4,3-e][1,3]oxazin-2-one antibiotics |
| IN2014CN04174A (en) | 2011-12-22 | 2015-09-04 | Novartis Ag | |
| NZ627750A (en) | 2012-01-06 | 2016-11-25 | Abide Therapeutics Inc | Carbamate compounds and of making and using same |
| GB201209587D0 (en) | 2012-05-30 | 2012-07-11 | Takeda Pharmaceutical | Therapeutic compounds |
| TW201422625A (en) | 2012-11-26 | 2014-06-16 | Novartis Ag | Solid form of dihydro-pyrido-oxazine derivative |
| TWI599567B (en) | 2013-03-14 | 2017-09-21 | 健生藥品公司 | P2X7 regulator |
| MA38588B1 (en) | 2013-04-16 | 2018-04-30 | Idorsia Pharmaceuticals Ltd | Bi-aromatic antibacterial derivatives |
| WO2016109501A1 (en) | 2014-12-30 | 2016-07-07 | Karos Pharmaceuticals, Inc. | Amide compounds as tryptophan hydroxylase inhibitors |
| US10106556B2 (en) | 2015-03-30 | 2018-10-23 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| US20180148429A1 (en) | 2015-05-13 | 2018-05-31 | Selvita S.A. | Substituted quinoxaline derivatives |
| WO2016185279A1 (en) | 2015-05-21 | 2016-11-24 | Glaxosmithkline Intellectual Property Development Limited | Benzoimidazole derivatives as pad4 inhibitors |
| EP3310773B1 (en) | 2015-06-18 | 2020-12-02 | 89Bio Ltd. | Substituted 4-benzyl and 4-benzoyl piperidine derivatives |
| MX375424B (en) | 2015-07-31 | 2025-03-06 | Pfizer | 1,1,1-TRIFLUORO-3-HYDROXYPROPAN-2-YL CARBAMATE DERIVATIVES AND 1,1,1-TRIFLUORO-4-HYDROXYBUTAN-2-YL CARBAMATE DERIVATIVES AS MAGL INHIBITORS |
| WO2017087858A1 (en) | 2015-11-20 | 2017-05-26 | Abide Therapeutics, Inc. | Pyrazole compounds and methods of making and using same |
| US10323038B2 (en) | 2015-11-20 | 2019-06-18 | Abide Therapeutics, Inc. | Pyrazole compounds and methods of making and using same |
| UY37174A (en) | 2016-03-31 | 2017-10-31 | Takeda Pharmaceuticals Co | A HETEROCYCLIC COMPOUND THAT HAS AN INHIBITING ACTION OF MONOACILGLICEROL LIPASA |
| WO2017170830A1 (en) * | 2016-03-31 | 2017-10-05 | 武田薬品工業株式会社 | Heterocyclic compound |
| EP3478678A1 (en) | 2016-06-30 | 2019-05-08 | Basilea Pharmaceutica International AG | Mitochondrial inhibitors for the treatment of proliferation disorders |
| PL3541807T3 (en) | 2016-11-16 | 2022-01-17 | H. Lundbeck A/S | A crystalline form of a magl inhibitor |
| JOP20190107A1 (en) | 2016-11-16 | 2019-05-09 | Lundbeck La Jolla Research Center Inc | monoacylglycerol lipase (MAGL) inhibitors |
| AU2018285131B2 (en) | 2017-06-12 | 2021-11-11 | Boehringer Ingelheim International Gmbh | Heteroaromatic compounds as Vanin inhibitors |
| AU2018338855B2 (en) | 2017-09-29 | 2022-04-28 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| AR114136A1 (en) | 2017-10-10 | 2020-07-29 | Hoffmann La Roche | HETEROCYCLIC COMPOUNDS |
| EP3717477B1 (en) | 2017-11-28 | 2022-07-20 | F. Hoffmann-La Roche AG | New heterocyclic compounds |
| TW201930300A (en) | 2017-12-15 | 2019-08-01 | 瑞士商赫孚孟拉羅股份公司 | New heterocyclic compounds |
| EP3737680A1 (en) | 2018-01-08 | 2020-11-18 | F. Hoffmann-La Roche AG | Octahydropyrido[1,2-alpha]pyrazines as magl inhibitors |
| DK3768684T3 (en) * | 2018-03-22 | 2023-04-24 | Hoffmann La Roche | Oxazine monoacylglycerol lipase (MAGL) inhibitors |
| EP3837264A1 (en) | 2018-08-13 | 2021-06-23 | F. Hoffmann-La Roche AG | New heterocyclic compounds as monoacylglycerol lipase inhibitors |
| MY210507A (en) | 2018-08-13 | 2025-09-28 | Hoffmann La Roche | New heterocyclic compounds as monoacylglycerol lipase inhibitors |
| EA202191432A1 (en) | 2018-11-22 | 2021-10-14 | Цилу Регор Терапьютикс Инк. | GLP-1R AGONISTS AND THEIR APPLICATIONS |
| WO2020104494A1 (en) | 2018-11-22 | 2020-05-28 | F. Hoffmann-La Roche Ag | New heterocyclic compounds |
| EP3953360B1 (en) | 2019-04-09 | 2024-02-28 | F. Hoffmann-La Roche AG | Heterocyclic compounds as inhibitors of monoacylglycerol lipase (magl) |
| CN114072405A (en) | 2019-07-03 | 2022-02-18 | 豪夫迈·罗氏有限公司 | Heterocyclic monoacylglycerol lipase (MAGL) inhibitors |
| KR20220034104A (en) | 2019-07-09 | 2022-03-17 | 에프. 호프만-라 로슈 아게 | Novel heterocyclic compounds |
| US20210094971A1 (en) | 2019-09-09 | 2021-04-01 | Hoffmann-La Roche Inc. | Heterocyclic compounds |
| PH12022550339A1 (en) | 2019-09-12 | 2023-03-13 | Hoffmann La Roche | 4,4a,5,7,8,8a-hexapyrido[4,3-b][1,4]oxazin-3-one compounds as magl inhibitors |
| WO2021048241A1 (en) | 2019-09-12 | 2021-03-18 | F. Hoffmann-La Roche Ag | Radiolabeled compounds |
| MX2022003023A (en) | 2019-09-23 | 2022-04-07 | Hoffmann La Roche | HETEROCYCLIC COMPOUNDS. |
| MX2022002831A (en) | 2019-09-24 | 2022-04-06 | Hoffmann La Roche | HETEROCYCLIC COMPOUNDS. |
| CA3152213A1 (en) | 2019-09-24 | 2021-04-01 | F. Hoffmann-La Roche Ag | New heterocyclic monoacylglycerol lipase (magl) inhibitors |
| WO2021058443A1 (en) | 2019-09-24 | 2021-04-01 | F. Hoffmann-La Roche Ag | Fluorescent probes for monoacylglycerol lipase (magl) |
| WO2022043284A1 (en) | 2020-08-26 | 2022-03-03 | F. Hoffmann-La Roche Ag | Heterocyclic compounds useful as magl inhibitors |
| PE20231372A1 (en) | 2020-09-03 | 2023-09-07 | Hoffmann La Roche | HETEROCYCLIC COMPOUNDS |
| AU2022260537A1 (en) | 2021-04-23 | 2023-09-21 | F. Hoffmann-La Roche Ag | Heterocyclic compounds |
-
2019
- 2019-08-12 MY MYPI2021000157A patent/MY210507A/en unknown
- 2019-08-12 PT PT197558554T patent/PT3837263T/en unknown
- 2019-08-12 SI SI201930813T patent/SI3837263T1/en unknown
- 2019-08-12 WO PCT/EP2019/071520 patent/WO2020035424A1/en not_active Ceased
- 2019-08-12 CN CN201980053749.3A patent/CN112867720A/en active Pending
- 2019-08-12 CR CR20210077A patent/CR20210077A/en unknown
- 2019-08-12 DK DK19755855.4T patent/DK3837263T3/en active
- 2019-08-12 MA MA53219A patent/MA53219B1/en unknown
- 2019-08-12 HR HRP20241201TT patent/HRP20241201T1/en unknown
- 2019-08-12 RU RU2021106145A patent/RU2769507C1/en active
- 2019-08-12 HU HUE19755855A patent/HUE067912T2/en unknown
- 2019-08-12 FI FIEP19755855.4T patent/FI3837263T3/en active
- 2019-08-12 ES ES19755855T patent/ES2986417T3/en active Active
- 2019-08-12 IL IL279173A patent/IL279173B2/en unknown
- 2019-08-12 EP EP19755855.4A patent/EP3837263B1/en active Active
- 2019-08-12 JP JP2021507457A patent/JP7637049B2/en active Active
- 2019-08-12 UA UAA202101016A patent/UA127629C2/en unknown
- 2019-08-12 SG SG11202013064WA patent/SG11202013064WA/en unknown
- 2019-08-12 EP EP24183419.1A patent/EP4474017A3/en active Pending
- 2019-08-12 BR BR112021002298-8A patent/BR112021002298A2/en unknown
- 2019-08-12 RS RS20240963A patent/RS65912B1/en unknown
- 2019-08-12 LT LTEPPCT/EP2019/071520T patent/LT3837263T/en unknown
- 2019-08-12 PE PE2021000135A patent/PE20211089A1/en unknown
- 2019-08-12 KR KR1020217004221A patent/KR102879259B1/en active Active
- 2019-08-12 CA CA3104928A patent/CA3104928A1/en active Pending
- 2019-08-12 MX MX2021001433A patent/MX2021001433A/en unknown
- 2019-08-12 PL PL19755855.4T patent/PL3837263T3/en unknown
- 2019-08-12 AU AU2019322538A patent/AU2019322538B2/en active Active
- 2019-08-13 TW TW108128734A patent/TWI812770B/en active
- 2019-08-13 AR ARP190102303A patent/AR116666A1/en unknown
-
2020
- 2020-04-09 US US16/844,262 patent/US20200308190A1/en not_active Abandoned
-
2021
- 2021-02-10 CL CL2021000362A patent/CL2021000362A1/en unknown
- 2021-02-11 PH PH12021500013A patent/PH12021500013A1/en unknown
- 2021-02-24 CO CONC2021/0002382A patent/CO2021002382A2/en unknown
-
2022
- 2022-05-20 US US17/749,496 patent/US11802133B2/en active Active
-
2023
- 2023-09-26 US US18/475,065 patent/US12281124B2/en active Active
-
2024
- 2024-09-06 JP JP2024153990A patent/JP2024174966A/en active Pending
-
2025
- 2025-02-28 US US19/066,414 patent/US20260022130A1/en active Pending
Non-Patent Citations (1)
| Title |
|---|
| SUPPLIER: UKRORGSYNTEZ LTD, KYIV., CAS REGISTRY NUMBER: 1941372-36-6, 29 June 2016 (2016-06-29) * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL279173B1 (en) | Heterocyclic compounds as monoacylglycerol lipase inhibitors, processes for their manufacture, pharmaceutical compositions comprising them, and uses thereof | |
| IL276031B2 (en) | Oxazine monoacylglycerol lipase (magl) inhibitors | |
| IL283333B2 (en) | Heterocyclic monoacylglycerol lipase inhibitors, processes for their manufacture, pharmaceutical compositions comprising them and their uses in the treatment or prophylaxis of neuroinflammation, neurodegenerative diseases, pain, cancer and mental disorders | |
| JP2021533093A (en) | A novel heterocyclic compound as a monoacylglycerol lipase inhibitor | |
| JP5820056B2 (en) | Cycloalkenyl aryl derivatives as CETP inhibitors | |
| US20210094943A1 (en) | Heterocyclic compounds | |
| SK14132002A3 (en) | Oxazole derivatives and their uses as tyrosine kinase inhibitors | |
| RU2013145299A (en) | Thiazolopyrimidines | |
| CN102264707A (en) | Novel bicyclic heterocyclic compound | |
| NZ594332A (en) | Compounds for the prevention and treatment of cardiovascular disease | |
| US20220098176A1 (en) | Heterocyclic compounds | |
| KR20220034104A (en) | Novel heterocyclic compounds | |
| RU2801190C2 (en) | New heterocyclic compounds as monoacylglycerol lipase inhibitors | |
| JP2025534292A (en) | Compounds for the treatment of central nervous system diseases or disorders | |
| RU2021105534A (en) | NEW HETEROCYCLIC COMPOUNDS AS MONOACYLGLYCEROL LIPASE INHIBITORS | |
| HK40062310A (en) | 4,4a,5,7,8,8a-hexapyrido[4,3-b][1,4]oxazin-3-one compounds as magl inhibitors | |
| NZ785586A (en) | Novel quinazolinones and related compounds for use as anti-inflammatory agents | |
| TW201412742A (en) | Novel inhibitor compounds of phosphodiesterase type 10A |